172,500 Shares in Cartesian Therapeutics, Inc. $RNAC Bought by Privium Fund Management B.V.

Privium Fund Management B.V. purchased a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 172,500 shares of the company’s stock, valued at approximately $1,244,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RNAC. AlphaQuest LLC increased its stake in Cartesian Therapeutics by 64.6% during the 3rd quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock worth $71,000 after buying an additional 2,717 shares during the period. R Squared Ltd purchased a new stake in Cartesian Therapeutics during the 4th quarter worth $74,000. Bank of America Corp DE increased its stake in Cartesian Therapeutics by 133.0% during the 2nd quarter. Bank of America Corp DE now owns 13,933 shares of the company’s stock worth $145,000 after buying an additional 7,952 shares during the period. Rhumbline Advisers increased its stake in Cartesian Therapeutics by 27.5% during the 1st quarter. Rhumbline Advisers now owns 13,006 shares of the company’s stock worth $171,000 after buying an additional 2,805 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Cartesian Therapeutics in the 3rd quarter worth about $256,000. Hedge funds and other institutional investors own 86.95% of the company’s stock.

Cartesian Therapeutics Stock Performance

RNAC opened at $7.39 on Wednesday. Cartesian Therapeutics, Inc. has a 1-year low of $5.60 and a 1-year high of $15.57. The company has a 50-day moving average of $6.87 and a 200-day moving average of $7.24. The company has a market capitalization of $217.12 million, a P/E ratio of -1.25 and a beta of 0.58.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.62). The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.22 million. As a group, sell-side analysts expect that Cartesian Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RNAC has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cartesian Therapeutics in a research report on Friday, March 27th. Needham & Company LLC reissued a “buy” rating and issued a $42.00 target price on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Wedbush reissued an “outperform” rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a research report on Friday, May 1st. Cantor Fitzgerald raised shares of Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 target price for the company in a research report on Monday, March 9th. Finally, BTIG Research reissued a “buy” rating on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Cartesian Therapeutics Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.